Fig. 3: Clinical correlates of immunomodulatory myeloid programs.
From: Programs, origins and immunomodulatory functions of myeloid cells in glioma
a, Quadrant plot with myeloid cells positioned as in Fig. 1e and coloured by the grade of the originating tumour. b, Box plot depicting the distribution of microglial inflammatory program module scores computed for 484 glioma datasets. For all the box plots in this figure, each dot represents a tumour, and lines represent median and quartiles. The whiskers represent 1.5 times the interquartile range. False discovery rate (FDR)-corrected P-values were calculated using two-sided Wilcoxon rank sum tests: *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant. Not all comparisons are shown. GBM, glioblastoma; LGG, low-grade glioma. c, Dot plot depicting the linear regression coefficient between the average usage of each myeloid program per glioma sample and the corresponding patient’s pre-surgery daily Dex dose. P-values are from ordinary least-squares regression model. d, Box plot showing average complement immunosuppressive program usage in glioma samples stratified by Dex dose; n = 37 IDH-WT glioma; P-values calculated using a two-sided Wilcoxon rank sum test. e, Box plot showing average usage of programs in glioma samples stratified by Dex use (hypoxic samples excluded). P-values were calculated using two-sided Wilcoxon rank sum tests. f, Box plot depicting the percentage of cells expressing the scavenger immunosuppressive program across glioma specimens from an anti-PD1 immunotherapy trial38, stratified by response (P = 0.017, FDR when considering all measurements in Extended Data Fig. 8f  = 0.088). g, Quadrant plots positioning the individual myeloid cells in f from radiographic response (left) and non-response (right) samples according to their expression of the immunomodulatory programs. h, Dot plot depicting the association between the indicated programs and Treg cell abundance across 85 gliomas. Adj. P-value, adjusted P-value. i, Kaplan–Meyer curve of overall survival for IDH-WT glioblastomas stratified by scavenger immunosuppressive program expression in GLASS54 and GSAM55 cohorts. The P-value was calculated using a two-sided log-rank test.
